Cover Image
市場調查報告書

全球API市場未來預測

Global API Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 276777
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
全球API市場未來預測 Global API Market Outlook 2020
出版日期: 2015年09月01日 內容資訊: 英文 85 Pages
簡介

全球API(Active Pharmaceutical Ingredient:醫藥品原料)市場,近幾年成長率顯著,預期2014年∼2020年以約6.5%的年複合成長率成長。

本報告提供全球API市場相關調查分析、產業的實際成果、各國比較分析、各治療市場區隔分析、新興機會和法規環境、主要企業簡介,為您概述為以下內容。

第1章 分析師的見解

第2章 調查手法

第3章 API:概要

第4章 全球API產業

第5章 推動市場成長要素與抑制因素

  • 成長推動因素
    • 老年人口的增加
    • 慢性疾病患者數的增加
    • 專利到期使學名藥用API的市場開放
    • 亞洲市場擁有的大幅成長可能性
  • 抑制因素
    • 價格上升使品牌醫藥品市場後退
    • 日益嚴格的法規環境
    • 產品核可流程的期間
    • 供應鏈缺乏透明度
  • 第6章 市場區隔
  • 各製造方法
    • 專屬市場
    • 商業市場
  • 各藥品類型
    • 學名藥用API
    • 品牌藥用API
  • API的種類
    • 商業性/小分子API
    • 生物TecAPI
  • 主要地區市場
    • 北美
    • 亞太地區
    • 歐洲
    • 其他地區
  • 治療領域
    • 循環系統疾病
    • 糖尿病
    • 中樞神經系統疾病
    • 腫瘤
    • 其他

第7章 產業趨勢

  • 提高溶解性的API的奈米晶體
  • 支撐API生產的技術進步

第8章 競爭情形

  • BASF SE
  • Kyowa Hakko Kirin
  • North China Pharmaceutical Group Corporation
  • Teva Active Pharmaceutical Ingredients
  • Lonza
  • Dr Reddy's Laboratories
  • Aurobindo Pharma Limited
  • Pfizer
  • Divis Laboratories Limited
  • Royal DSM
  • Boehringer Ingelheim GmbH

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global API market has been garnering a lot of attention since the last few years. In our report “Global API Market Outlook 2020”, the growth of the global API market has been forecasted by looking at the current market trends. This market is expected to grow at a CAGR of 6.5% from 2014-2020. The market has been segmented by type of manufacturing, type of drug, type of API and by therapeutic segment; and each segment's market has also been forecasted.

The market has been divided into four major geographies which comprise of North America, Asia Pacific, Europe and the Rest of the World. For every region, the current and future outlook of the API sector has been provided. A future opportunity assessment of every region has also been done to help highlight the areas with promising possibilities.

Excellent growth has been witnessed in pharmaceutical industry in emerging markets. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand of pharmaceuticals. However, major regulatory changes in the United States and Europe are set to change the API landscape. As patterns in developed regions continue to remain flat and opportunities for growth shift from traditional markets, the API industry is expected to witness the rise of second wave emerging markets, such as India and China.

As the days of the blockbuster drugs start waning, more flexible manufacturing focused on personalized medicine can be seen as the future of the pharmaceutical business. The report elaborates on the rise of more such trends and challenges, and their possible impacts on the industry.

We have also covered the key players in the Merchant API Market. For every player, a brief business overview, geographical revenue break up, and segment-wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global API market.

Table of Contents

1. Analyst View

2. Research Methodology

3. APIs - An Introduction

4. Global API Industry

5. Drivers & Challenges

  • 5.1 Drivers
    • 5.1.1 Rise in Geriatric Population
    • 5.1.2 Increasing Prevalence of Chronic Diseases
    • 5.1.3 Patent Expiry Opening Market for Generic APIs
    • 5.1.4 Asian Markets Offer Considerable Growth Potential
  • 5.2 Challenges
    • 5.2.1 Surging Prices Holding Back Branded Drug Market
    • 5.2.2 Increasingly Challenging Regulatory Environment
    • 5.2.3 Lengthy Product Approval Process
    • 5.2.4 Lack of Transparency in Supply Chain

6. Market Segmentation

  • 6.1 By Type of Manufacturing
    • 6.1.1 Captive Market
    • 6.1.2 Merchant Market
  • 6.2 By Type of Drug
    • 6.2.1 Generic Drug API
    • 6.2.2 Branded Drug API
  • 6.3 By Type of API
    • 6.3.1 Chemical/Small Molecule API
    • 6.3.2 Biotech API
  • 6.4 By Key Geographical Markets
    • 6.4.1 North America
    • 6.4.2 Asia-Pacific
    • 6.4.3 Europe
    • 6.4.4 Rest of the World
  • 6.5 By Therapeutic Segments
    • 6.5.1 Cardiovascular Diseases
    • 6.5.2 Diabetes
    • 6.5.3 Central Nervous System Disorders
    • 6.5.4 Oncology
    • 6.5.5 Others

7. Trends and Developments

  • 7.1 Nanocrystals of APIs to Improve Solubility
  • 7.2 Technological Advancements Aiding API Production

8. Competitive Landscape

  • 8.1 BASF SE
  • 8.2 Kyowa Hakko Kirin
  • 8.3 Teva Active Pharmaceuticals Ingredients
  • 8.4 Lonza
  • 8.5 Dr. Reddy's Laboratories
  • 8.6 Aurobindo Pharma Limited
  • 8.7 Pfizer
  • 8.8 Divis Laboratories Limited
  • 8.9 Royal DSM
  • 8.10 Boehringer Ingelheim GmbH

List of Figures:

  • Figure 4-1: Global - API Market (Billion US$), 2014-2020
  • Figure 5-1: Worldwide Population above 60 Years (Billion), 2014 & 2050
  • Figure 5-2: US - Population Suffering from Chronic Condition (Million), 2014 & 2020
  • Figure 6-1: Global - Share of Captive and Merchant Market in API Market (2014)
  • Figure 6-2: Global - API Captive Market (Billion US$), 2014-2020
  • Figure 6-3: Global - API Merchant Market (Billion US$), 2014-2020
  • Figure 6-4: Global - Share of Branded and Generic Market in API Market (2014)
  • Figure 6-5: Global - Generic API Market (Billion US$), 2014-2020
  • Figure 6-6: Global - Branded API Market (Billion US$), 2014-2020
  • Figure 6-7: Global - Share of Synthetic and Biotech APIs in API Market (2014)
  • Figure 6-8: Global - Chemical/Small Molecule API Market (Billion US$), 2014-2020
  • Figure 6-9: Global - Biotech API Market (Billion US$), 2014-2020
  • Figure 6-10: North America - API Market (Billion US$), 2014-2020
  • Figure 6-11: Asia-Pacific - API Market (US$ Billion), 2014-2020
  • Figure 6-12: Europe - API Market (Billion US$), 2014-2020
  • Figure 6-13: ROW - API Market (Billion US$), 2014-2020
  • Figure 6-14: Breakup of Global API Market by Therapeutic Segments (%), 2014
  • Figure 8-1: BASF SE - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-2: Kyowa Hakko Kirin - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-3: Teva Pharmaceutical Industries Limited - Break up of Revenue by Geographical Segment (%), 2014
  • Figure 8-4: Lonza - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-5: Dr. Reddy's Laboratories - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-6: Aurobindo Pharma Limited - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-7: Pfizer - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-8: Divis Laboratories Limited - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-9: Royal DSM - Break up of Revenue by Geographic Origin (%), 2014
  • Figure 8-10: Boehringer Ingelheim GmbH - Break up of Revenue by Geographic Segment (%), 2014

List of Tables:

  • Table 3-1: Classification of Bulk Drugs
  • Table 5-1: Blockbuster Drugs Going Off Patent (2014-2015)
  • Table 8-1: BASF SE - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-2: Kyowa Hakko Kirin - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-3: Teva Pharmaceutical Industries Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-4: Lonza - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-5: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-7: Pfizer - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-8: Divis Laboratories Limited - Revenues (Billion US$), 2013 & 2014
  • Table 8-9: Royal DSM - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-10: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Back to Top